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Abstract
Background: glutathione (GSH) is the most abundant thiol antioxidant in mammalian cells. It
directly reacts with reactive oxygen species (ROS), functions as a cofactor of antioxidant enzymes,
and maintains thiol redox potential in cells. GSH depletion has been implicated in the pathogenesis
of neurological diseases, particularly to Parkinson's disease (PD). The purpose of this study was to
investigate the change of cellular antioxidant status and basic cell functions in the relatively early
stages of GSH depletion.
Results: in this study, GSH was depleted by inhibition of glutamylcysteine synthetase using
buthionine sulfoximine (BSO) treatment in Ht22, a neuronal cell line derived from mouse
hippocampus. Treatment with BSO produced dose-dependent decreases in total GSH level, Fe3+-
reducing ability (FRAP assay), Cu2+-reducing ability (Antioxidant Potential, AOP assay), and ABTS
free radical scavenging ability (ABTS assay) of the cells, but the sensitivity of these indicators to
dosage varied considerably. Most of the changes were completed during the first 8 hours of
treatment. Cell viability was tested by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromid) assay, and cells at lower density in culture were found to be more sensitive to GSH
depletion. The activity of antioxidant enzymes, such as glutathione peroxidase (GPx), glutathione
reductase (GR), and copper/zinc superoxide dismutase (Cu/Zn-SOD) were affected by GSH
depletion. A cDNA expression array assay of the effects of BSO treatment showed significantly
decreased mRNA level for 3 genes, and significantly increased mRNA level for 10 genes, including
the antioxidant enzymes Cu/Zn-SOD and thioredoxin peroxidase 2 (TPxII).
Conclusions: the study suggests that there are BSO-sensitive and BSO-resistant pools of GSH in
Ht22 cells, and that different categories of antioxidant react differently to GSH depletion. Further,
the effect of GSH status on cell viability is cell density dependent. Finally, the alterations in
expression or activity of several antioxidant enzymes provide insight into the various cellular
responses to GSH depletion.
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Glutathione (GSH, tripeptide γ-L-glutamyl-L-cysteinyl-
glycine) is the most abundant thiol antioxidant in mam-
malian cells. It reacts directly with reactive oxygen species
(ROS), or functions as a cofactor of antioxidant enzymes
such as the glutathione peroxidases (GPxs). In addition,
GSH keeps sulfhydryl groups of cytosolic proteins in
reduced form by maintaining thiol redox potential in cells
[1], and regulates cell signaling pathway in apoptosis
[2,3]. The requirement for GSH and total antioxidant
capacity is particularly high in brain.
Brain consumes 20% of total oxygen in the body, and thus
undergoes high levels of oxidative challenge. Cumulative
oxidative damage has been strongly implicated in neuro-
degeneration and neurological diseases, such as Parkin-
son's disease (PD), Alzheimer's disease (AD), and
amyotrophic lateral sclerosis (ALS). The importance of
GSH in particular has been indicated in the case of PD.
Among the progressive oxidative stresses that occur in the
pathogenesis of PD, an characteristic is the decrease in
total GSH concentrations in the substantia nigra in pre-
clinical stages, when other biochemical changes are still
undetectable [4].
Investigation of the consequences of intracellular GSH
depletion in neuronal cell lines has relied predominantly
on one of three methods. These are: (a) treatment with
homocysteic acid (HCA) or glutamate to block the uptake
of cystine, a substrate for GSH synthesis [5-7]; (b) treat-
ment with BSO [5] to inactivate γ-glutamylcysteine syn-
thetase, the rate limiting enzyme in GSH synthesis, and
(c) treatment with ethacrynic acid [8] or diethyl maleate
[9] to react with the thiol group of GSH. The oxidative
stress caused by GSH depletion further affects the status of
other antioxidants. The concept of total antioxidant
capacity (TAC) has been developed to assess the general
antioxidant activity in biological samples without distin-
guishing the contribution from each individual compo-
nent. Measurements of TAC have been intensively
developed in the past 20 years. The principle of these
methods is to evaluate the total effect of all contributing
compounds in the system by one criterion, such as free
radical scavenging, electron donation or protection
against the oxidative damage to lipids, proteins or DNA.
But considering the fact that different categories of anti-
oxidant work through different mechanisms and need
specified conditions for maximal function, it is impossi-
ble to cover the activities of all antioxidants in one assay.
Thus multi-dimensional measurements on TAC have
been suggested [10].
In this study, GSH was depleted by BSO in Ht22, a neuro-
nal cell line derived from mouse hippocampus. GSH
level, TAC, antioxidant enzyme activity, cell viability and
gene expression were assessed.
Results and discussion
Intracellular total GSH level vs. cell density in culture
Before depleting GSH from cells, total GSH levels in Ht22
were monitored from pre-log phase to the end of log
phase of cell growth (Figures 1 &2). Intracellular GSH
Growth curve of Ht22 cellsFigure 1
Growth curve of Ht22 cells. Cell number counted by hemo-
cytometer, three counts for each point.
Total intracellular GSH concentration in Ht22 cellsFigure 2
Total intracellular GSH concentration in Ht22 cells. The 
GSH levels decrease with increasing cell density in culture.Page 2 of 8
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being more dramatic as the cells entered log phase growth.
Whether the decrease of GSH with cell growth is due to
limited nutrient supply or to programmed regulation is
not known. It has been reported that the GSH content of
brain cells depends strongly on the availability of precur-
sors for GSH [11]. It was also noticed that as Ht22 cells
grow denser in culture, the intracellular ROS level
decreased (Chen et al., unpublished data), as apparently
balances with the decreased GSH concentration.
Dose responses
Intracellular GSH
The dose responses of Ht22 to BSO were analyzed by var-
ying BSO concentration from 0.03 to 10 mM in a 15-hr
treatment, and the changes of intracellular GSH level and
TAC were measured (Figure 3). Treatment with 0.03 mM
BSO resulted in a dramatic decrease of total GSH level to
35% of the control level. Increasing the BSO concentra-
tion to 10 mM further decreased the GSH level to 22% of
control, representing an additional drop of only 13%. In
comparison to 0.03 mM of BSO, increasing the concentra-
tion to 1 mM or higher caused significant decreases in
GSH levels (P values ≤ 0.0399). This result suggests there
are two pools of GSH in the cell, one easily depleted by
BSO, and the other more resistant to depletion. A previous
study by Seyfried et al. [12] showed that BSO treatment of
PC12 cells was more efficient at depleting cytosolic GSH
than mitochondrial GSH, indicating that the BSO-sensi-
tive and BSO-resistant GSH pools in Ht22 might localize
to cytosol and mitochondria, respectively.
After 10 mM BSO treatment for 15 hrs, the predominant
form of glutathione was the reduced form (GSH); only
about 5% of the total glutathione was found in the oxi-
dized form (GSSG). After 15 hrs BSO treatment, malond-
ialdehyde (MDA) assay showed the increases of Abs at
586 nm caused by MDA formation were: control = 0.011
± 0.006; 1 mM BSO = 0.012 ± 0.006; 3 mM BSO = 0.009
± 0.004; and 10 mM BSO = 0.011 ± 0.004 (average ± SD,
3–5 independent experiments), no increase in lipid per-
oxidation after the treatments was observed, indicating
GSH depletion at these levels was not yet destructive to
the cells.
Total antioxidant capacity
Three methods were employed in this study to investigate
antioxidant status following BSO treatment of Ht22 cells.
The Cu2+-reducing ability assay (Antioxidant Potential,
AOP) and Fe3+-reducing ability assay (FRAP) both meas-
ure the activity of metal ion-reducing antioxidants, but the
FRAP assay is characterized by its low pH (3.7), thus
excluding the antioxidant function of thiols. Figure 3
shows that from 0.03 to 10 mM BSO treatment, the FRAP
value had a sharp decrease from 76 to 32% of the control,
indicating that some non-thiol antioxidants were
expended to preserve the BSO-resistant GSH or to cope
with oxidative stress caused by the depletion of BSO-sen-
sitive GSH. In comparison to FRAP, the AOP value
showed a gradual decrease from 76 to 50 % of control
through the range of BSO concentrations, and this lesser
decrease may be partially maintained by the BSO-resistant
GSH pool in the cells.
In contrast to FRAP and AOP, the ABTS free radical scav-
enging ability (ABTS assay) of the cells maintained at
about 80% of the control level at all BSO concentrations.
Cao et al. [13] previously showed that GSH is highly reac-
tive to ABTS radical. Unlike the FRAP and AOP assays, the
ABTS assay appears to be less sensitive to the metal ion-
reducing antioxidants that were consumed by GSH
depletion.
Cell viabilities and bioreduction activity
Cell viabilities
Effects of GSH depletion on cell viability were assayed
using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromid)-based cell viability assay, an
indicator of mitochondrial activity (Figure 4). Ht22 cells
at higher density (1e5 cells per well, equal to 1.3e5 cells
per square cm) were more resistant to GSH depletion, and
in spite of the change in BSO concentration, the decrease
Dose response of Ht22 cells to BSO treatmentFigure 3
Dose response of Ht22 cells to BSO treatment. The effects 
of 15-hour BSO treatment on GSH level and total antioxi-
dant capacity in Ht22 cells were measured. Average value 
and SD are shown, N = 3. In comparison to 0.03 mM of BSO, 
increasing the concentration to 1 mM or higher caused signif-
icant decreases in GSH levels (P values ≤ 0.0399).Page 3 of 8
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cell density (5e4 cells per well, equal to 6.5e4 cells per
square cm) rendered higher sensitivity; as BSO concentra-
tion increased from 0.03 to 10 mM, the viability dropped
from 100 to 50% of control. At 3 and 10 mM BSO concen-
trations, the differences caused by cell density are signifi-
cant (P values ≤ 0.0027). These results show that the
mitochondrial activity of cells is influenced by GSH deple-
tion, and that this effect is sensitive to the density of cells
in culture. The reason(s) behind the cell density factor is
not clear. Either proliferation status or communication
between cells may contribute. In neurodegenerative dis-
eases, the effect of cell death, thus the decrease of cell den-
sity, on the susceptibility of neurons to GSH depletion
will be worth investigating. Wither sever cell death can
accelerate GSH loss is not known.
No changes in cell viability in response to BSO treatment
were detected by trypan blue staining, which distinguishes
dead cells from live ones. Cell viabilities were 98.9% (N =
25) for untreated cells, and 99.6% (N = 5), 99.1% (N = 5),
and 98.1% (N = 12), after 15 hrs treatment with 1, 5, and
10 mM BSO, respectively. The oxidative stress produced in
these treatments is not sufficient to be lethal to the cells,
in accordance with the MDA assay, which shows no
increase in lipid peroxidation.
Bioreduction activity
Figure 5 shows a slight tendency of increase in the biore-
duction activity in cells after BSO treatment, as is more
evident when cells were at lower density. The effective
resazurin-reducing compound(s) in Ht22 is not clear, but
the possible background from BSO was excluded. The
mechanism behind the change is yet to be understood.
Time course
The responses of Ht22 cells to 0.1 mM BSO treatment
were tested at 4, 8, 12 and 15 hrs, and results are expressed
as percentage of 0 hr (Figure 6). For total GSH, FRAP and
ABTS, 4-hr treatment induced significant decreases (P val-
ues ≤ 0.0001), while AOP value did not change signifi-
cantly. From 4 hrs to 8 hrs, all of the assays showed
significant decreases (P values ≤ 0.0326). Whereas from 8
through 15 hrs, no significant change was seen. The data
suggests that for 0.1 mM BSO treatment, the majority of
the GSH depletion occurred in the first 8 hrs, and that the
depletion of other antioxidants were dynamically parallel
to GSH depletion. Cell death was visible under micros-
copy after 20 hrs of 0.1 or 10 mM BSO treatments.
Seyfried et al. [12] found that PC12 cells treated with 0.5
mM BSO maintained 100 % of mitochondrial GSH in the
first 4 hrs, while cytosolic GSH was completely depleted.
Extending the treatment from 4 hrs to 6 hrs resulted in 50
% depletion of mitochondrial GSH. These data are in
agreement with the significant decreases of total GSH
level from 0 to 4 hrs, and from 4 hrs to 8 hrs in this study,
MTT assay for the viability of Ht22 cells treated with BSO for 15 hoursFigure 4
MTT assay for the viability of Ht22 cells treated with BSO for 
15 hours. Average value and SD are shown (1e5 cells/ well, N 
= 9; 5e4 cells/ well, N = 5). At 3 and 10 mM BSO concentra-
tions, the differences caused by cell density are significant (P 
values ≤ 0.0027).
Resazurin based bioreduction assay of Ht22 cells treated with BSO for 15 h ursFigure 5
Resazurin based bioreduction assay of Ht22 cells treated 
with BSO for 15 hours. Average value and SD are shown 
(1e5 cells/ well, N = 6; 5e4 cells/ well, N = 5). For 1e5 cells/
well, treatment of 0.03 mM BSO caused significant increase 
in the bioreduction activity vs control (P = 0.0053); for 5e4 
cells/well, the increases caused by treatments of 0.1 and 3 
mM BSO were significant vs control (P ≤ 0.0175).Page 4 of 8
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Glutathione peroxidases (GPxs) are selenium-containing
antioxidant enzymes that reduce hydrogen peroxide to
water, or lipid peroxides to ethanols, with GSH as reduc-
ing cofactor. Five isoforms of the GPx family are com-
monly known. In this study, the major activity detected by
the assay is cellular GPx (GPx1). Figure 7 shows the
change of GPx activity in response to 1, 3 and 10 mM BSO
treatments for 15 hrs. Treatment with 1 mM BSO signifi-
cantly increased the GPx activity to 127% of control (P =
0.0401). Treatment with 3 or 10 mM BSO decreased the
activity by about 20% of control. This treatment was not
significant compared to control, but is significant when
compared to 1 mM BSO treatment (P values ≤ 0.0421).
The results show that the regulation of GPx activity is
dependent on the level of GSH depletion, and that the
reserve pool of GSH may have critical function, since
slight depletion caused significant changes.
Glutathione reductase
Glutathione reductase (GR) reduces GSSG to GSH using
NADPH as cofactor. When Ht22 cells were subjected to 1,
3 and 10 mM BSO treatment for 15 hrs, the GR activity in
the cells dropped to 97%, 95% and 94% of control,
respectively (Figure 8). At 10 mM BSO concentration, the
decrease is significant (P = 0.045) in comparison to the
Time course of the responses of Ht22 cells to BSO treatmentF gure 6
Time course of the responses of Ht22 cells to BSO treat-
ment. The effects of total GSH level and total antioxidant 
capacities of Ht22 cells treated with 0.1 mM BSO for 4, 8, 12, 
and 15 hours were measured. Average value and SD are 
shown, N = 3. For total GSH, FRAP and ABTS, 4-hr treat-
ment induced significant decreases vs control (P values ≤ 
0.0001); from 4 hrs to 8 hrs, all of the assays showed signifi-
cant decreases (P values ≤ 0.0326).
GPx activity of Ht22 cells treated with BSO for 15 hoursFigure 7
GPx activity of Ht22 cells treated with BSO for 15 hours. 
Average value and SD are shown, N = 3. Treatment with 1 
mM BSO significantly increased the GPx activity vs control (P 
= 0.0401); and the decreases caused by 3 or 10 mM BSO are 
significant vs 1 mM BSO treatment (P values ≤ 0.0421).
GR activity of Ht22 cells treated with BSO for 15 hoursFigure 8
GR activity of Ht22 cells treated with BSO for 15 hours. 
Average value and SD are shown, N = 3. At 10 mM BSO con-
centration, the decrease is significant (P = 0.045) vs control.Page 5 of 8
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array study in Section 5 did not show significant changes
in the mRNA level of GR. The activity decrease of this
enzyme may be due to enzyme inactivation caused by oxi-
dative stress.
Superoxide dismutase
Superoxide dismutase (SOD) converts superoxide anion
to hydrogen peroxide, which can be further detoxified by
GPx1 or catalase. Two isoforms of SOD are found in
mammalian cells, known as Cu/Zn-SOD and Mn-SOD,
and localized in cytosol and mitochondria, respectively.
Incubating Ht22 cells with 1, 3, and 10 mM BSO for 15
hrs increased the Cu/Zn-SOD activity to 104%, 112%,
and 152% (P= 0.0619) of the control level (Figure 9). The
toxicology cDNA expression array study found a 2-fold
increase of Cu/Zn-SOD mRNA level in response to treat-
ment with 10 mM BSO treatment. In contrast to GPx,
SOD responds more to severe GSH depletion or higher
level of oxidative stress.
Toxicology cDNA expression array
cDNA expression arrays are powerful tools for studying
gene expression under various circumstances. In this
study, we employed the Atlas rat toxicology array II (BD)
to monitor the changes in gene expression after 15 hrs
treatment with 10 mM BSO. Out of a total of 465 genes in
the array, mRNA level of 3 genes were significantly
decreased, and 10 significantly increased (Table 1). The
increased mRNA level of heat shock protein (HSP, the
induction of which correlates with the abundance of
unfolded polypeptide chains) and eukaryotic peptide
chain release factor 1 (ERF1, which functions in termina-
tion of translation) indicate the stress caused by BSO treat-
ment affected proteins at translational and structural
levels. The increased mRNA level of antioxidant enzymes
Cu/Zn-SOD and thioredoxin peroxidase 2 (TPx II, a per-
oxidase that requires thioredoxin or thiol-containing
intermediates to carry out its peroxidase function) sug-
gests these enzymes have important functions in coping
with the oxidative stress caused by GSH depletion. Fur-
thermore, both of these enzymes have been shown to pro-
tect cells from different inducers of apoptosis [14,15],
indicating that they may have contributed to maintaining
high cell viability after BSO treatment in this study.
Conclusions
Inhibition of glutamylcysteine synthetase in Ht22 cells by
BSO revealed two pools of GSH in the cells, one
susceptible to depletion by low concentration of BSO, and
the other more resistant to depletion. TAC values
measured by FRAP, AOP and ABTS methods showed par-
allel time courses to GSH depletion, but different dose-
responses. The GSH depletion studied did not result in
increases in GSH/GSSG ratio, lipid peroxidation, or cell
death, but affected MTT-based cell viability. The antioxi-
dant enzyme activities of GPx, GR and Cu/Zn-SOD were
affected by the GSH depletion. The mRNA levels of
HSP90-beta, ERF1, Cu/Zn-SOD and TPx II were signifi-
cantly increased after 10 mM BSO-15 hr treatment.
Methods
Cell maintenance and treatment
Ht22 cells were fed with Dulbecco's Modified Eagle
Medium (DMEM) with 10% fetal bovine serum (FBS)
supplement, and cultured at 50–55% relative humidity
(RH), in 5% CO2 at 37°C. For MTT-based cell viability
assay and Resazurin-based bioreduction activity assay,
cells were seeded at a density of 1 or 0.5 million cells per
well (corresponding to 1.3e5 and 6.5e4 cells per square
cm, respectively) in 48-well cell culture plates (Costar) 12
hrs before BSO treatment. For other assays, the cells were
allowed to reach 80–90% of optical confluency (about
2e5 cells per square cm) in 100 mm cell culture dishes
(Costar) before the BSO treatment.
TAC, GSH/GSSG, MDA assays
In this study, three methods were employed for total anti-
oxidant capacity assay. The AOP assay (Antioxidant
Potential assay kit, Oxis) tests the ability of samples to
reduce Cu2+ to Cu+ at physiological pH, (assayed
according to manufacturer's instructions with minor
adjustments). The FRAP assay [16] tests the ability of
samples to reduce Fe3+ to Fe2+ at pH 3.6, a low pH that
inactivates thiol antioxidants. The ABTS assay [17] tests
Cu/Zn-SOD activity of Ht22 cells treated with BSO for 15 hoursFigure 9
Cu/Zn-SOD activity of Ht22 cells treated with BSO for 15 
hours. Average value and SD are shown, N = 3. Treatment of 
10 mM BSO caused a trend of increase in SOD activity vs 
control (P = 0.0619).Page 6 of 8
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physiological pH. Modified versions [18] of FRAP and
ABTS assays were used in this study. GSH was assayed for
total level as well as GSH/GSSG ratio using GSH/GSSG
ratio assay kit (Oxis). Manufacturer's instructions were
followed with minor adjustments. Lipid peroxidation in
cells was assayed using malondialdehyde (MDA), a prod-
uct of lipid peroxide decomposition, as an indicator. The
assay was carried out using a Malondialdehyde assay kit
(Oxis).
Cell viabilities and bioreduction activity assays
A common method of testing cell viability is trypan blue
staining. As a vital dye, trypan blue enters dead cells, dis-
tinguishing them from live ones. In this study, 0.4% (w/
v) trypan blue-PBS solution was mixed with properly
diluted cells at 5:1 ratio, and cell numbers were counted
using a hemocytometer. Cell viability can also be reflected
by dehydrogenase activity, which indicates the activity of
mitochondria (Cell growth determination kit/MTT based,
Sigma). Dehydrogenase converts MTT into purple MTT
formazan, causing a colorimetric change that can be
monitored photometrically. The bioreduction activity of
cells was monitored by an in vitro toxicology assay kit
(Sigma), based on a blue to red color change when the
oxidoreduction dye, resazurin, is reduced by the bioreduc-
tion activity of the cells. Both MTT and Resazurin assays
were carried out following the kit instructions.
GPx, GR, and SOD activity assays
GPx activity assay was based on the classical principle [19]
with optimization to the Ht22 cell lysis. The peroxide
used in this study was t-butyl hydroperoxide (0.323 mM),
the concentration of GSH was reduced to 1.875 mM, and
the pH of the assay was increased to 7.6. The GR and SOD
activities were assayed by corresponding kits from Oxis.
Toxicology cDNA array assay
Atlas rat toxicology array II was purchased from BD, and
the assay was carried out following the instruction
manual.
Statistical work
F-test in SAS procedure "Proc GLM" was used for statistical
work.
Authors' contributions
JC designed experiments, treated and harvested samples,
optimized and participated in the antioxidant assays, par-
ticipated in the toxicology cDNA array assay. ASH partici-
Table 1: Genes with significantly changed mRNA levels after BSO treatment. The results were detected by Atlas rat toxicology array 









heat shock cognate 71-kDa protein (HSC73; HSC70) Y00054 1773 4780 2.70
eukaryotic peptide chain release factor subunit 1 (ERF1); 
TB3-1; C11 protein [rat homolog of human]
M75715 (human) 208 519 2.50
thioredoxin peroxidase 2 (TDPX2); thioredoxin-
dependent peroxide reductase 2; heme-binding 23-kDa 
protein (HBP23)
D30035 1710 3989 2.33
78-kDa glucose-regulated protein precursor (GRP78); 
immunoglobulin heavy chain binding protein (BIP); 
steroidogenesis-activator polypeptide; HSPA5
M14050 66 154 2.33
60S ribosomal protein L6 (RPL6) X87107 1932 4353 2.25
copper-zinc-containing superoxide dismutase 1 (Cu-Zn 
SOD1)
Y00404 1285 2813 2.19
proliferating cell nuclear antigen (PCNA); cyclin Y00047 1463 3210 2.19
thymosin beta-10 (TMSB10; THYB10); PTMB10 M17698 3545 7637 2.15
high mobility group protein 2 (HMG2) D84418 957 1976 2.06
heat shock 90-kDa protein beta (HSP90-beta); HSP84; 
HSPCB
S45392 7737 15881 2.05
mRNA decreased
DNA topoisomerase IIB (TOP2B) D14046 4146 1502 0.36
osteopontin M14656 3630 1535 0.42
contrapsin-like protease inhibitor related protein; SPI-3 
serine protease inhibitor
D00753 13996 5961 0.43Page 7 of 8
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